查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2085929

液態生物檢體市場：2026-2032年全球市場預測（按生物標記、檢體、類型、技術、適應症、最終用戶和應用分類）

Liquid Biopsy Market by Biomarkers, Sample, Type, Technology, Indication, End-User, Application - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，液態生物檢體市場將成長至 173.1 億美元，複合年成長率為 12.63%。

主要市場統計數據
基準年 2025 75.2億美元
預計年份：2026年 84.4億美元
預測年份 2032 173.1億美元
複合年成長率 (%) 12.63%

液態生物檢體執行摘要

液態生物檢體透過分析循環腫瘤DNA、循環性腫瘤細胞、遊離DNA、RNA、甲基化特徵、外泌體以及其他來自血液和其他體液的分析物，正在重新定義精準腫瘤學的概念。與傳統的組織切片檢查不同，液態生物檢體即使在組織樣本不可用、不足或難以取得的情況下，也能實現創傷較小的取樣、時間序列監測和更快速的分子分析。

液態生物檢體的革命性變革

液態切片領域正從單基因突變檢測轉向更廣泛的多分析、多體學平台。實驗室和診斷公司正在將ctDNA突變譜分析與甲基化、片段組體學、表觀基因訊號、蛋白質組學和人工智慧等技術結合，以提高各癌症階段的敏感性和臨床意義。

人工智慧的累積影響

人工智慧透過提高低濃度腫瘤成分訊號檢測的準確性、降低定序雜訊以及輔助解讀複雜的基因組和表觀基因組模式，進一步增強了液態生物檢體的應用價值。機器學習模型擴大用於變異檢測、甲基化分類、腫瘤起源預測和風險分層，尤其在ctDNA水平有限的早期疾病中發揮效用。

關鍵區域洞察：液態生物檢體的全球普及情況

北美憑藉其先進的腫瘤學基礎設施、完善的分子病理學網路、FDA監管路徑、大規模臨床試驗活動以及與保險公司在伴隨診斷和基因組分析方面的合作，仍然是液態生物檢體。美國透過精準醫療計畫、癌症中心網路以及將液態生物檢體整合到腫瘤藥物研發中，引領著液體活體組織切片的普及應用；而加拿大則透過其省級癌症醫療保健系統、集中式檢查室模式以及基於循證醫學的保險報銷審查，穩步推進液體活體組織切片的發展。

關鍵群體特定見解：策略性液態生物檢體叢集

在東協地區，液態生物檢體的需求受到癌症發病率上升、醫療旅遊中心興起、私人診斷網路擴張以及腫瘤專科醫生診療服務改善等因素的推動。然而，各國在保險報銷、檢查室標準化和監管協調方面仍存在差異。海灣合作理事會（GCC）成員國正在投資精準醫療、公共衛生、先進的腫瘤中心和數位醫療基礎設施，為高品質的液態生物檢體服務、本地檢驗以及與診斷機構和大學附屬醫院的合作創造了有利環境。

重點國家洞察：首選液態生物檢體市場

美國正引領分子腫瘤學的商業化進程，這得益於FDA批准的檢測方法、伴隨診斷的應用、腫瘤學指南的採納以及生物製藥公司在臨床試驗中的應用。加拿大則透過集中式癌症計畫、省級檢測路徑和實證評估不斷推進分子腫瘤學的發展。墨西哥和巴西的私人實驗室、與參考實驗室的合作以及對擴大分子腫瘤學服務覆蓋範圍的日益關注，都在推動分子腫瘤學的發展。在英國、德國、法國、義大利和西班牙，液態生物檢體的應用正透過國家基因組策略、癌症網路、分子腫瘤學委員會和衛生技術評估（HTA）框架不斷擴展。俄羅斯市場則受到國內檢測能力、區域癌症醫療基礎設施以及部分國際技術取得管道有限的限制。

為行業領導者提供的實用建議

產業領導者應優先考慮具有明確臨床效用，例如晚期癌症的治療方案、抗藥性監測以及有前瞻性研究證據支持的微小殘留病灶（MRD）檢測項目。產品藍圖應使檢測效能與預期用途相匹配，包括檢​​測極限、腫瘤百分比要求、檢體處理規範、結果報告時間、報告清晰度以及腫瘤科醫生解讀的便捷性。

調查方法

本執行摘要採用系統化的二手調查方法編寫，重點關注檢驗的、公開可用的和行業認可的資訊來源。這些資訊來源包括監管資料庫和來自美國FDA和歐洲監管機構等組織的公告、來自NCCN、ASCO和ESMO等腫瘤學組織的臨床指南、關於腫瘤學和分子診斷的同行評審文獻、臨床試驗註冊資訊、最新的保險報銷資訊、來自WHO和OECD等組織的公共衛生資料集，以及次世代定序、ctDNA分析、甲基化譜分析和人工智慧領域的生物開發學分析和人工智慧領域的生物統計分析。

結論：液態生物檢體的實證發展

由於液態生物檢體活體組織切片比組織切片檢查操作更簡便，且能即時獲取分子層面的信息，因此已成為精準腫瘤學的核心支柱。儘管目前最大的價值在於治療方案的選擇、抗藥性的檢測和時間序列監測，但早期癌症檢測和多癌種篩檢仍具有巨大的潛力，需要嚴格的檢驗、謹慎的實施以及明確的臨床獲益證據。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：液態生物檢體市場：依生物標記分類

  • 無細胞DNA
  • 循環性腫瘤細胞
  • 循環腫瘤DNA
  • 細胞外囊泡

第8章：液態生物檢體市場：以樣本量分類

  • 血液衍生的
  • 尿液來源的

第9章：液態生物檢體市場：按類型分類

  • 檢測試劑盒
  • 裝置
  • 服務

第10章：液態生物檢體市場：依技術分類

  • 利用NGS進行多基因平行分析
  • 利用PCR微陣列進行單一基因分析

第11章：液態生物檢體市場：依適應症分類

  • 癌症適應症
    • 乳癌
    • 結腸癌
    • 肺癌
    • 黑色素瘤
    • 攝護腺癌
  • 除癌症以外的其他適應症

第12章：液態生物檢體市場：依最終用戶分類

  • 學術和研究機構
  • 臨床診斷檢查室
  • 醫院
  • 臨床檢查室

第13章：液態生物檢體市場：按應用領域分類

  • 早期癌症篩檢
  • 復發監測
  • 治療方案
  • 治療監測

第14章：液態生物檢體市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第15章：液態生物檢體市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章：液態生物檢體市場：按國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第18章：公司簡介

  • ANGLE PLC
  • Bio-Rad Laboratories, Inc.
  • Bio-Techne Corporation
  • Biocartis NV
  • Danaher Corporation
  • DiaCarta, Inc.
  • Dxcover Limited
  • Epic Sciences Inc.
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche Ltd.
  • GENCURIX
  • Guardant Health, Inc.
  • Illumina, Inc.
  • Labcorp Holdings Inc.
  • Laboratory Dr. med. Pachmann
  • Lucence Health Inc.
  • LungLife AI, Inc.
  • MDxHealth SA
  • Menarini Silicon Biosystems SpA
  • Merck KGaA
  • Myriad Genetics, Inc.
  • Natera, Inc.
  • NeoGenomics Laboratories, Inc.
  • OncoDNA SA
  • PerkinElmer, Inc.
  • Personalis, Inc.
  • QIAGEN NV
  • SAGA Diagnostics AB
  • Strand Life Sciences Pvt Ltd.
  • Sysmex Corporation
  • Tempus AI, Inc.
  • Thermo Fisher Scientific Inc.
Product Code: MRR-43470FC608C8

The Liquid Biopsy Market is projected to grow by USD 17.31 billion at a CAGR of 12.63% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 7.52 billion
Estimated Year [2026] USD 8.44 billion
Forecast Year [2032] USD 17.31 billion
CAGR (%) 12.63%

Liquid Biopsy Executive Summary

Liquid biopsy is redefining precision oncology by enabling analysis of circulating tumor DNA, circulating tumor cells, cell-free DNA, RNA, methylation signatures, exosomes, and other analytes from blood or other body fluids. Unlike conventional tissue biopsy, liquid biopsy can support less invasive sampling, longitudinal monitoring, and faster molecular profiling when tissue is unavailable, insufficient, or difficult to access.

The field has moved from exploratory research to clinical utility, supported by U.S. FDA-authorized companion diagnostics, broad use of next-generation sequencing, and increasing guideline recognition in advanced cancers. Demand is strongest in therapy selection, resistance monitoring, minimal residual disease assessment, recurrence surveillance, and emerging multi-cancer early detection applications, where evidence quality, analytical sensitivity, and clinical validity remain decisive adoption factors.

Transformative Shifts in Liquid Biopsy

The liquid biopsy landscape is shifting from single-gene mutation testing toward broader multi-analyte, multi-omics platforms. Laboratories and diagnostics developers are combining ctDNA mutation profiling with methylation, fragmentomics, epigenomic signals, proteomics, and AI-enabled interpretation to improve sensitivity and clinical relevance across cancer stages.

Regulatory and reimbursement expectations are also transforming adoption. FDA-cleared and FDA-approved tests have strengthened physician confidence, while payers increasingly require evidence of clinical utility, outcome improvement, and cost-effectiveness. At the same time, decentralized blood collection, biopharma partnerships, and clinical trial stratification are expanding use beyond late-stage oncology into recurrence risk, treatment response, and screening, particularly in settings where repeat tissue biopsy is clinically impractical.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is compounding the impact of liquid biopsy by improving signal detection in low-abundance tumor fractions, reducing sequencing noise, and supporting interpretation of complex genomic and epigenomic patterns. Machine learning models are increasingly used for variant calling, methylation classification, tumor-origin prediction, and risk stratification, especially where early-stage disease produces limited ctDNA.

AI also supports operational scalability through automated quality control, bioinformatics workflow optimization, laboratory workflow prioritization, and clinical decision support. However, adoption depends on transparent validation, bias assessment across populations, data governance, cybersecurity, and compliance with evolving AI and medical device regulations. The most defensible AI-enabled liquid biopsy strategies are those anchored in prospective clinical evidence, reproducible model performance, and traceable analytical validation.

Key Regional Insights: Global Liquid Biopsy Adoption

North America remains a leading liquid biopsy region due to advanced oncology infrastructure, established molecular pathology networks, FDA regulatory pathways, major clinical trial activity, and payer engagement around companion diagnostics and genomic profiling. The United States anchors adoption through precision medicine programs, cancer center networks, and integration of liquid biopsy into oncology drug development, while Canada shows steady implementation through provincial oncology systems, centralized laboratory models, and evidence-based reimbursement review.

Europe is shaped by strong academic oncology, the EU In Vitro Diagnostic Regulation, and national health technology assessment processes that emphasize clinical validity, clinical utility, and quality management. Asia-Pacific is expanding as China, Japan, South Korea, India, and Australia invest in genomic medicine, local sequencing capacity, cancer screening infrastructure, and advanced oncology care. Latin America is progressing through private-sector testing, reference-lab partnerships, and expanding molecular oncology awareness, while the Middle East is accelerating precision oncology through national transformation programs, advanced hospital systems, and investment in genomic medicine. Africa remains earlier in adoption, with opportunities centered on access, sample logistics, oncology workforce development, laboratory accreditation, and regional reference laboratories that can improve availability of liquid biopsy testing.

Key Group Insights: Strategic Liquid Biopsy Clusters

Within ASEAN, liquid biopsy demand is supported by rising cancer burden, medical tourism hubs, expanding private diagnostics networks, and improving access to oncology specialists, although reimbursement, laboratory standardization, and cross-country regulatory alignment remain uneven. The GCC is investing in precision medicine, population health, advanced oncology centers, and digital health infrastructure, creating favorable conditions for premium liquid biopsy services, localized validation, and partnerships with diagnostic providers and academic hospitals.

The European Union is defined by IVDR compliance, cross-border cancer research, quality assurance requirements, and evidence-led reimbursement, making analytical validation and demonstrated clinical utility essential for scale. BRICS countries are important growth engines because of large patient populations, local sequencing capabilities, government interest in biotechnology self-sufficiency, and expanding cancer care capacity. G7 markets lead in clinical trial adoption, regulatory sophistication, reimbursement scrutiny, and oncology guideline integration, while NATO countries benefit from overlapping healthcare modernization, biomedical research funding, laboratory interoperability initiatives, and secure data infrastructure that can strengthen genomic medicine and liquid biopsy implementation.

Key Country Insights: Priority Liquid Biopsy Markets

The United States leads commercialization through FDA-authorized assays, companion diagnostic use, oncology guideline adoption, and biopharma use in clinical trials. Canada is advancing through centralized cancer programs, provincial testing pathways, and evidence-based assessment, while Mexico and Brazil show growing private-lab adoption, reference laboratory partnerships, and increasing interest in expanding molecular oncology access. The United Kingdom, Germany, France, Italy, and Spain are building liquid biopsy use through national genomics strategies, cancer networks, molecular tumor boards, and health technology assessment discipline; Russia's market is shaped by domestic testing capacity, regional oncology infrastructure, and constrained access to some international technologies.

China is scaling local liquid biopsy innovation through high-volume oncology demand, domestic sequencing capacity, and regulatory attention to advanced diagnostics. India is expanding access through urban oncology centers, cost-sensitive laboratory models, and rising demand for precision cancer care. Japan and South Korea benefit from strong precision medicine ecosystems, regulatory maturity, advanced cancer care infrastructure, and active oncology research networks. Australia supports adoption through guideline-driven oncology practice, academic research, established molecular pathology networks, and structured evaluation of new diagnostic technologies.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize indications with clear clinical utility, such as therapy selection in advanced cancer, resistance monitoring, and measurable residual disease programs backed by prospective evidence. Product roadmaps should align assay performance with intended use, including limits of detection, tumor fraction requirements, sample handling specifications, turnaround time, reporting clarity, and interpretability for oncologists.

Commercial success will depend on payer-ready evidence, regulatory-quality validation, laboratory accreditation, and partnerships with cancer centers, biopharma sponsors, and reference laboratories. Organizations should invest in interoperable bioinformatics, transparent AI governance, diverse clinical datasets, real-world evidence generation, and patient-friendly blood collection models. Regional strategies should be tailored to reimbursement maturity, oncology infrastructure, local regulatory requirements, and clinical workflow readiness rather than relying on one global commercialization template.

Research Methodology

This executive summary is developed using a structured secondary research methodology focused on verified, publicly available, and industry-recognized sources. Inputs include regulatory databases and announcements from agencies such as the U.S. FDA and European authorities; clinical guidance from oncology organizations including NCCN, ASCO, and ESMO; peer-reviewed oncology and molecular diagnostics literature; clinical trial registries; reimbursement updates; public health datasets from sources such as WHO and OECD; and documented technology developments in next-generation sequencing, ctDNA analysis, methylation profiling, and AI-enabled bioinformatics.

Insights are triangulated across regulatory milestones, clinical adoption signals, technology trends, regional healthcare infrastructure, guideline evolution, reimbursement conditions, and peer-reviewed evidence. The analysis excludes unsupported market claims and emphasizes evidence-backed interpretation of liquid biopsy applications, including companion diagnostics, ctDNA profiling, minimal residual disease, recurrence monitoring, treatment response assessment, and early detection research.

Conclusion: Evidence-Led Growth in Liquid Biopsy

Liquid biopsy has become a central pillar of precision oncology because it offers a practical route to real-time molecular insight with lower procedural burden than tissue biopsy. Its strongest current value lies in therapy selection, resistance detection, and longitudinal monitoring, while early cancer detection and multi-cancer screening remain high-potential areas requiring rigorous validation, careful implementation, and clear evidence of clinical benefit.

The next phase of leadership will be defined by clinical evidence, regulatory credibility, AI-enabled analytical performance, reimbursement alignment, and equitable access. Organizations that combine scientifically validated assays with payer-aligned outcomes, regional execution, robust laboratory quality systems, and trustworthy data infrastructure will be best positioned to shape the future of liquid biopsy.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Liquid Biopsy Market, by Biomarkers

  • 7.1. Cell-free DNA
  • 7.2. Circulating Tumor Cells
  • 7.3. Circulating Tumor DNA
  • 7.4. Extracellular Vesicles

8. Liquid Biopsy Market, by Sample

  • 8.1. Blood Based
  • 8.2. Urine Based

9. Liquid Biopsy Market, by Type

  • 9.1. Assay Kits
  • 9.2. Instruments
  • 9.3. Services

10. Liquid Biopsy Market, by Technology

  • 10.1. Multi-gene Parallel Analysis using NGS
  • 10.2. Single-gene Analysis using PCR Microarrays

11. Liquid Biopsy Market, by Indication

  • 11.1. Cancer Indication
    • 11.1.1. Breast Cancer
    • 11.1.2. Colorectal Cancer
    • 11.1.3. Lung Cancer
    • 11.1.4. Melanoma
    • 11.1.5. Prostate Cancer
  • 11.2. Non-Cancer Indication

12. Liquid Biopsy Market, by End-User

  • 12.1. Academic & Research Centers
  • 12.2. Clinical Diagnostic Laboratories
  • 12.3. Hospitals
  • 12.4. Physician's Office Laboratories

13. Liquid Biopsy Market, by Application

  • 13.1. Early Cancer Screening
  • 13.2. Recurrence Monitoring
  • 13.3. Therapy Selection
  • 13.4. Treatment Monitoring

14. Liquid Biopsy Market, by Region

  • 14.1. Asia-Pacific
  • 14.2. North America
  • 14.3. Latin America
  • 14.4. Europe
  • 14.5. Middle East
  • 14.6. Africa

15. Liquid Biopsy Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Liquid Biopsy Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025

18. Company Profiles

  • 18.1. ANGLE PLC
  • 18.2. Bio-Rad Laboratories, Inc.
  • 18.3. Bio-Techne Corporation
  • 18.4. Biocartis NV
  • 18.5. Danaher Corporation
  • 18.6. DiaCarta, Inc.
  • 18.7. Dxcover Limited
  • 18.8. Epic Sciences Inc.
  • 18.9. Exact Sciences Corporation
  • 18.10. F. Hoffmann-La Roche Ltd.
  • 18.11. GENCURIX
  • 18.12. Guardant Health, Inc.
  • 18.13. Illumina, Inc.
  • 18.14. Labcorp Holdings Inc.
  • 18.15. Laboratory Dr. med. Pachmann
  • 18.16. Lucence Health Inc.
  • 18.17. LungLife AI, Inc.
  • 18.18. MDxHealth SA
  • 18.19. Menarini Silicon Biosystems SpA
  • 18.20. Merck KGaA
  • 18.21. Myriad Genetics, Inc.
  • 18.22. Natera, Inc.
  • 18.23. NeoGenomics Laboratories, Inc.
  • 18.24. OncoDNA SA
  • 18.25. PerkinElmer, Inc.
  • 18.26. Personalis, Inc.
  • 18.27. QIAGEN N.V.
  • 18.28. SAGA Diagnostics AB
  • 18.29. Strand Life Sciences Pvt Ltd.
  • 18.30. Sysmex Corporation
  • 18.31. Tempus AI, Inc.
  • 18.32. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL LIQUID BIOPSY MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL LIQUID BIOPSY MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL LIQUID BIOPSY MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL LIQUID BIOPSY MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL LIQUID BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL LIQUID BIOPSY MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL LIQUID BIOPSY MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL LIQUID BIOPSY MARKET SIZE, BY TYPE, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL LIQUID BIOPSY MARKET SIZE, BY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL LIQUID BIOPSY MARKET SIZE, BY END-USER, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL LIQUID BIOPSY MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL LIQUID BIOPSY MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL LIQUID BIOPSY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL LIQUID BIOPSY MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL LIQUID BIOPSY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 27. GLOBAL LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL LIQUID BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CELL-FREE DNA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CELL-FREE DNA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CELL-FREE DNA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CIRCULATING TUMOR CELLS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CIRCULATING TUMOR CELLS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CIRCULATING TUMOR CELLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CIRCULATING TUMOR DNA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CIRCULATING TUMOR DNA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CIRCULATING TUMOR DNA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL EXTRACELLULAR VESICLES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL EXTRACELLULAR VESICLES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL EXTRACELLULAR VESICLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BLOOD BASED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BLOOD BASED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BLOOD BASED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL URINE BASED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL URINE BASED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL URINE BASED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ASSAY KITS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ASSAY KITS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ASSAY KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL INSTRUMENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL INSTRUMENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL INSTRUMENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL MULTI-GENE PARALLEL ANALYSIS USING NGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL MULTI-GENE PARALLEL ANALYSIS USING NGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL MULTI-GENE PARALLEL ANALYSIS USING NGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL SINGLE-GENE ANALYSIS USING PCR MICROARRAYS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL SINGLE-GENE ANALYSIS USING PCR MICROARRAYS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL SINGLE-GENE ANALYSIS USING PCR MICROARRAYS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CANCER INDICATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CANCER INDICATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CANCER INDICATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BREAST CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BREAST CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BREAST CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL COLORECTAL CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL COLORECTAL CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL COLORECTAL CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL LUNG CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL LUNG CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL LUNG CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL MELANOMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL MELANOMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL MELANOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL PROSTATE CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL PROSTATE CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL PROSTATE CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL NON-CANCER INDICATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL NON-CANCER INDICATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL NON-CANCER INDICATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ACADEMIC & RESEARCH CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ACADEMIC & RESEARCH CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ACADEMIC & RESEARCH CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CLINICAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CLINICAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CLINICAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL PHYSICIAN'S OFFICE LABORATORIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL PHYSICIAN'S OFFICE LABORATORIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL PHYSICIAN'S OFFICE LABORATORIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL EARLY CANCER SCREENING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL EARLY CANCER SCREENING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL EARLY CANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL RECURRENCE MONITORING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL RECURRENCE MONITORING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL RECURRENCE MONITORING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL THERAPY SELECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL THERAPY SELECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL THERAPY SELECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL TREATMENT MONITORING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL TREATMENT MONITORING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL TREATMENT MONITORING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL LIQUID BIOPSY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. ASIA-PACIFIC LIQUID BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 89. ASIA-PACIFIC LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2032 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA LIQUID BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA LIQUID BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE LIQUID BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST LIQUID BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 130. MIDDLE EAST LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA LIQUID BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 135. AFRICA LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2032 (USD MILLION)
  • TABLE 136. AFRICA LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. AFRICA LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 138. AFRICA LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 139. AFRICA LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
  • TABLE 140. AFRICA LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 141. AFRICA LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL LIQUID BIOPSY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 143. ASEAN LIQUID BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 145. ASEAN LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2032 (USD MILLION)
  • TABLE 146. ASEAN LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 149. ASEAN LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 151. ASEAN LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 152. GCC LIQUID BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 153. GCC LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 154. GCC LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2032 (USD MILLION)
  • TABLE 155. GCC LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. GCC LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 157. GCC LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 158. GCC LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
  • TABLE 159. GCC LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 160. GCC LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPEAN UNION LIQUID BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPEAN UNION LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPEAN UNION LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPEAN UNION LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPEAN UNION LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPEAN UNION LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPEAN UNION LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 170. BRICS LIQUID BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 171. BRICS LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 172. BRICS LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2032 (USD MILLION)
  • TABLE 173. BRICS LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. BRICS LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 175. BRICS LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 176. BRICS LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
  • TABLE 177. BRICS LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 178. BRICS LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 179. G7 LIQUID BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 180. G7 LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 181. G7 LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2032 (USD MILLION)
  • TABLE 182. G7 LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. G7 LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 184. G7 LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 185. G7 LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
  • TABLE 186. G7 LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 187. G7 LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 188. NATO LIQUID BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 189. NATO LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 190. NATO LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2032 (USD MILLION)
  • TABLE 191. NATO LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. NATO LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 193. NATO LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 194. NATO LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
  • TABLE 195. NATO LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 196. NATO LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 197. GLOBAL LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 198. UNITED STATES LIQUID BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 199. UNITED STATES LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 200. UNITED STATES LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2032 (USD MILLION)
  • TABLE 201. UNITED STATES LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. UNITED STATES LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 203. UNITED STATES LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 204. UNITED STATES LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
  • TABLE 205. UNITED STATES LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 206. UNITED STATES LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 207. CANADA LIQUID BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 208. CANADA LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 209. CANADA LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2032 (USD MILLION)
  • TABLE 210. CANADA LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. CANADA LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 212. CANADA LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 213. CANADA LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
  • TABLE 214. CANADA LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 215. CANADA LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 216. MEXICO LIQUID BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 217. MEXICO LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 218. MEXICO LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2032 (USD MILLION)
  • TABLE 219. MEXICO LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 220. MEXICO LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 221. MEXICO LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 222. MEXICO LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
  • TABLE 223. MEXICO LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 224. MEXICO LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 225. BRAZIL LIQUID BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 226. BRAZIL LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 227. BRAZIL LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2032 (USD MILLION)
  • TABLE 228. BRAZIL LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 229. BRAZIL LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 230. BRAZIL LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 231. BRAZIL LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
  • TABLE 232. BRAZIL LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 233. BRAZIL LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 234. UNITED KINGDOM LIQUID BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 235. UNITED KINGDOM LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 236. UNITED KINGDOM LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2032 (USD MILLION)
  • TABLE 237. UNITED KINGDOM LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 238. UNITED KINGDOM LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 239. UNITED KINGDOM LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 240. UNITED KINGDOM LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
  • TABLE 241. UNITED KINGDOM LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 242. UNITED KINGDOM LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 243. GERMANY LIQUID BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 244. GERMANY LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 245. GERMANY LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2032 (USD MILLION)
  • TABLE 246. GERMANY LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 247. GERMANY LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 248. GERMANY LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 249. GERMANY LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
  • TABLE 250. GERMANY LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 251. GERMANY LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 252. FRANCE LIQUID BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 253. FRANCE LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 254. FRANCE LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2032 (USD MILLION)
  • TABLE 255. FRANCE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 256. FRANCE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 257. FRANCE LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 258. FRANCE LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
  • TABLE 259. FRANCE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 260. FRANCE LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 261. RUSSIA LIQUID BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 262. RUSSIA LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 263. RUSSIA LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2032 (USD MILLION)
  • TABLE 264. RUSSIA LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 265. RUSSIA LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 266. RUSSIA LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 267. RUSSIA LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
  • TABLE 268. RUSSIA LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 269. RUSSIA LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 270. ITALY LIQUID BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 271. ITALY LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 272. ITALY LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2032 (USD MILLION)
  • TABLE 273. ITALY LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 274. ITALY LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 275. ITALY LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 276. ITALY LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
  • TABLE 277. ITALY LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 278. ITALY LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 279. SPAIN LIQUID BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 280. SPAIN LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 281. SPAIN LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2032 (USD MILLION)
  • TABLE 282. SPAIN LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 283. SPAIN LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 284. SPAIN LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 285. SPAIN LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
  • TABLE 286. SPAIN LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 287. SPAIN LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 288. CHINA LIQUID BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 289. CHINA LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 290. CHINA LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2032 (USD MILLION)
  • TABLE 291. CHINA LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 292. CHINA LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 293. CHINA LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 294. CHINA LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
  • TABLE 295. CHINA LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 296. CHINA LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 297. INDIA LIQUID BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 298. INDIA LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 299. INDIA LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2032 (USD MILLION)
  • TABLE 300. INDIA LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 301. INDIA LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 302. INDIA LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 303. INDIA LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
  • TABLE 304. INDIA LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 305. INDIA LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 306. JAPAN LIQUID BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 307. JAPAN LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 308. JAPAN LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2032 (USD MILLION)
  • TABLE 309. JAPAN LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 310. JAPAN LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 311. JAPAN LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 312. JAPAN LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
  • TABLE 313. JAPAN LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 314. JAPAN LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 315. AUSTRALIA LIQUID BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 316. AUSTRALIA LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 317. AUSTRALIA LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2032 (USD MILLION)
  • TABLE 318. AUSTRALIA LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 319. AUSTRALIA LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 320. AUSTRALIA LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 321. AUSTRALIA LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
  • TABLE 322. AUSTRALIA LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 323. AUSTRALIA LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 324. SOUTH KOREA LIQUID BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 325. SOUTH KOREA LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 326. SOUTH KOREA LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2032 (USD MILLION)
  • TABLE 327. SOUTH KOREA LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 328. SOUTH KOREA LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 329. SOUTH KOREA LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 330. SOUTH KOREA LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
  • TABLE 331. SOUTH KOREA LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 332. SOUTH KOREA LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)